Thomas G. Evans MD

Dr. Thomas G. Evans received his MD from the University of Virginia and trained in Internal Medicine at UCSF, and in Infectious Diseases back in Virginia.

Tom established a laboratory during his first position at the University of Utah and directed the HIV clinic. He moved to the University of Rochester as Associate Professor for 5 years, before becoming Infectious Diseases Division Chief and tenured full Professor at the University of California, Davis. His academic research centered on leishmania and HIV vaccine development and led to him joining Vical, a DNA vaccine developer as Chief Medical Officer in 2002. In 2005 he joined the Novartis Institutes for Biomedical Research as Global Head of Infectious Diseases Translational Medicine and Research. In September 2008 he moved to Shanghai as VP for Translational Sciences in Asia for Novartis. In September 2010, Tom joined Aeras, a non-profit Product Development Partnership with a mission to develop global tuberculosis vaccines, as the Chief Scientific Officer, and became CEO in February 2013. He has over 150 authored publications.

Tom joined Vaccitech as a director in the spring of 2016 and served as CEO from April 2017 to August 2019. Having successfully built Vaccitech to a late clinical-stage biopharmaceutical company as CEO, in his role as CSO, Tom focuses more specifically on the science, research, and development that underpin Vaccitech’s next-generation T cell induction products.